John Herlihy, MD
Gastroenterology · Cedar Rapids, IANPI 1245625151
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,510 of the $13,114 with a category attached, or 87.8%. 49 manufacturers reported payments, led by AbbVie at 25.6% of the total. Reporting peaked in 2024 at $4,001 and has fallen 62.4% since, to $1,504 in 2025. Among gastroenterology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 575 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Genentech USA, Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Gilead$874
- Regeneron Healthcare Solutions, Inc.$583
- Boston Scientific$431
- plus $5K from 43 others
Across 3 payments — averaging $3000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$9K
What the payments were for
- Travel & lodging$1,58212%
- Food & beverage$11,51088%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,114 in reported general payments places this provider in the 95th percentile of 113 gastroenterology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 12 | $305,417 |
| LinzessLinaclotide | 130 | $174,054 |
| Humira(Cf) PenAdalimumab | 19 | $147,153 |
| IbsrelaTenapanor Hcl | 46 | $99,941 |
| XifaxanRifaximin | 33 | $92,263 |
| CreonLipase/Protease/Amylase | 12 | $45,038 |
| TrulancePlecanatide | 34 | $42,199 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 88 | $14,025 |
| Dexlansoprazole DrDexlansoprazole | 20 | $7,979 |
| Sucralfate | 35 | $7,545 |
| Esomeprazole Magnesium | 130 | $6,607 |
| Lubiprostone | 32 | $4,214 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 18 | $3,122 |
| Omeprazole | 137 | $2,498 |
| Tetracycline Hcl | 14 | $1,615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $874 | $305,41712 claims |
| AbbVieLinzess, Creon | $3,363 | $219,092142 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,345 | $134,46167 claims |
| Ardelyx, Inc.Ibsrela | $193 | $99,94146 claims |
| Braintree Laboratories, Inc.Sutab | $185 | $14,02588 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $28 | $3,12218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 113 gastroenterology providers in Iowa.
Other gastroenterology in Cedar Rapids
- Ujjwal KumarCedar Rapids$4K
- Bhavya AkhauriCedar Rapids$2K
- Nathalie Pena PolancoCedar Rapids$2K
- Barakat Aburajab AltamimiCedar Rapids$2K
- Leon QiaoCedar Rapids$789
- Douglas PurdyCedar Rapids$765
- Nagendra MyneniClive$66K
- Ryan PerumpailBettendorf$62K
- Richard ManfreadyWaterloo$56K
- Maen MasadehIowa City$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.